MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.26
+0.23
+4.57%
Closed 16:00 03/02 EST
OPEN
5.09
PREV CLOSE
5.03
HIGH
5.54
LOW
5.07
VOLUME
668.81K
TURNOVER
--
52 WEEK HIGH
9.15
52 WEEK LOW
1.900
MARKET CAP
217.59M
P/E (TTM)
-2.5948
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?
Zacks.com · 21h ago
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected...
BusinessWire - BZX · 1d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 5d ago
Adamas Pharmaceuticals stock under pressure on $55M equity raise
Adamas Pharmaceuticals (ADMS) -7% premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an additional 1.875M shares.Offering is expected to close on
Seekingalpha · 5d ago
Adamas Pharmaceuticals Focuses on Therapies for Neurological Diseases >ADMS
Adamas Pharmaceuticals Focuses on Therapies for Neurological Diseases >ADMS
Dow Jones · 6d ago
Adamas: SVB Leerink, William Blair Are Bookrunning Managers for Offering; JMP Securities Is Lead Manager >ADMS
Adamas: SVB Leerink, William Blair Are Bookrunning Managers for Offering; JMP Securities Is Lead Manager >ADMS
Dow Jones · 6d ago
Adamas Pharmaceuticals Offering Expected to Close March 1 >ADMS
Adamas Pharmaceuticals Offering Expected to Close March 1 >ADMS
Dow Jones · 6d ago
Adamas Pharmaceuticals Selling All Shares in Offering >ADMS
Adamas Pharmaceuticals Selling All Shares in Offering >ADMS
Dow Jones · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMS. Analyze the recent business situations of Adamas Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMS stock price target is 10.44 with a high estimate of 20.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 18.54M
% Owned: 60.66%
Shares Outstanding: 41.37M
TypeInstitutionsShares
Increased
21
1.74M
New
19
534.75K
Decreased
17
837.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Director
John MacPhee
Director
Spyridon Papapetropoulos
Director
Anna Richo
Independent Director
Michael Bigham
Independent Director
Bill Ericson
Independent Director
Martha Demski
Independent Director
Mardi Dier
Independent Director
William Ericson
  • Dividends
  • Splits
  • Insider Activity
No Data
About ADMS
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.